reports
Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-T
goetzpartners securities Limited Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-T 28-Sep-2018 / 07:39 GMT/BST Free to access research and investor meetings in a post-MiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients. Published to the market and investors on 28th September 2018 @ 7.17am (London time). Â Actinium Pharmaceuticals Inc (ATNM-US): Impro...
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate P...
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board. The following nuclear medicine physicians and scientists have joined the Company’s advisory board: MemberMedical Institution Affiliation David Colcher, Ph.D. City of HopeJohannes Czernin, M.D.UCLAGhassan El-Haddad, M.D.Moffitt Cancer Ce...
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD cli...
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse with a need for improved consolidation therapiesWebcast to be held on July 10, 2018 at 8:00 AM ET to discuss planned trial featuring Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section at Columbia University Medical Center who is leading this effort NEW YORK, July 09, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on ...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM ET to discuss planned trial featuring Dr. Joseph Jurcic, Director of the Hematologic Malignancies Section at Columbia University Medical Center who is leading this effort NEW YORK, June 28, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM)...
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Perce...
Actinium Pharmaceuticals Announces Dosing of 38th Patient and 25 Percent Enrollment in Iomab-B Pivotal SIERRA Trial Iomab-B remains the only targeted conditioning treatment in clinical trials with the potential to increase access to and improve outcomes of bone marrow transplant NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has dosed the 38th patient in the pivotal Phase 3 SIERRA (Study of Iomab-B in Elderly Relapse Refractory Acute Myeloid Leukemia) study of Iomab-B, rea...
Actinium Provides Update from Society of Nuclear Medicine and Molecula...
Actinium Provides Update from Society of Nuclear Medicine and Molecular Imaging Annual Meeting Two Nuclear Medicine focused advisory boards have been formed to provide expertise and strategic guidance to Actinium Meeting with Iomab-B and Actimab investigators to be held to provide trial updates and discuss outlook for clinical development NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), today highlighted the Company’s activities at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting ...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M - Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for this program - Phase 1 trial at Medical College of Wisconsin is studying combination of Actinium’s Actimab-A with CLAG-M salvage regimen in patients with relapsed/refractory AML NEW YORK, June 13, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A...
Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML Clinical trial to be conducted by the Medical College of Wisconsin as an investigator initiated trial led by Dr. Sameem Abedin in collaboration with Dr. Ehab Atallah Combination trial expands addressable patient population for Actinium’s CD33 program into relapsed or refractory patients fit for chemotherapy NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announce...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Update: Promising data from Actimab-A Phase I/II study
Actinium Pharmaceuticals is progressing two compounds, Iomab-B and Actimab-A, through the clinic for the treatment of blood cancers, with a further three programmes in preclinical development. Actimab-A has successfully completed Cohort 3 of the first part of the Phase I/II trial underway in elderly patients with newly diagnosed AML. The encouraging clinical outcomes, coupled with a promising toxicity profile, suggest it should progress to Phase II once the maximum dose is established.
Update: Public offering to fund late-stage development
Actinium Pharmaceuticals is developing targeted radiation therapies (both alpha and beta particle based) that offer the prospect of highly selective tumour cell killing with limited side effects compared to existing therapies. The underwritten public offering consists of 4.44m shares and 3.33m warrants (exercisable over four years) at a combined price of $4.50. The $20m (gross) raised will be used to progress the late-stage clinical programmes to key value inflection points, notably Iomab-B in a...
Update: Iomab-B on track for Phase III
Actinium Pharmaceuticals has started production of clinical batches of Iomab-B ahead of initiating a pivotal Phase III study. Iomab-B, a beta radio-emitter, could start this trial, for use as a conditioning agent for hematopoietic stem cell transplantation (HSCT, bone marrow transplant) instead of chemotherapy and/or whole body radiation, in mid-15. Phase I/II results suggested the overall survival rate at one year of patients over 55 with AML could be increased from c 10% to c 30% with Iomab-B ...
Update: Actinium Pharmaceuticals
Actinium Pharmaceuticals has reported encouraging interim results from the Phase I/II study currently underway for Actimab-A in the US. Actimab-A is a targeted payload therapeutic that uses a monoclonal antibody to deliver precisely a powerful α radiation emitter for treating acute myeloid leukaemia (AML). Seven patients with secondary AML due to prior myelodysplastic syndrome (MDS) had a median overall survival (OS) of 9.1 months (range 2.4 to 24 months), against typical survival of 2 to 5 mon...
Initiation: Radiating potential
Actinium Pharmaceuticals is developing a portfolio of radio-labelled antibodies to treat various cancers. Its lead product, Iomab-B, is due to start a pivotal Phase III trial in H115 for use as a conditioning agent before hematopoietic stem cell therapy (HSCT, bone marrow transplantation) in elderly relapsed/refractory acute myeloid leukaemia (AML) patients. Its other clinical product, Actimab-A, is in a Phase I/II trial in newly diagnosed AML in the elderly; interim data from this trial are due...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.